DR info

Clinical trials : 39 / Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95

Fibrodysplasia ossificans progressiva and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)

ID	Diseases (Sorted by score)	Score
272	Fibrodysplasia ossificans progressiva	-
6	Parkinson disease	19.011
140	Dorabe syndrome	17.308
13	Multiple sclerosis/Neuromyelitis optica	17.280
144	Lennox-Gastaut syndrome	17.268
193	Prader-Willi syndrome	17.195
298	Hereditary pancreatitis	17.126
70	Spinal stenosis	16.783
156	Rett syndrome	16.583
97	Ulcerative colitis	16.030
152	PCDH19 related syndrome	16.000
96	Crohn disease	15.934
201	Angelman syndrome	14.322
205	Fragile X syndrome related disease	13.785
145	West syndrome	13.493
22	Moyamoya disease	13.363
155	Acquired aphasia with convulsive disorder	13.241
2	Amyotrophic lateral sclerosis	13.041
231	Alpha-1-antitrypsin deficiency	12.659
158	Tuberous sclerosis	12.659
8	Huntington disease	12.306
34	Neurofibromatosis	12.265
98	Eosinophilic gastrointestinal disease	12.248
296	Biliary atresia	12.034
18	Spinocerebellar degeneration	12.034
21	Mitochondrial disease	11.941
36	Epidermolysis bullosa	11.856
3	Spinal muscular atrophy	11.704
206	Fragile X syndrome	11.670
46	Malignant rheumatoid arthritis	11.656
17	Multiple system atrophy	11.460
75	Cushing disease	11.434
5	Progressive supranuclear palsy	11.361
84	Sarcoidosis	11.047
58	Hypertrophic cardiomyopathy	3.385
67	Polycystic kidney disease	2.113
167	Marfan syndrome	1.969
81	Congenital adrenal hyperplasia	1.744
51	Scleroderma	1.630
86	Pulmonary arterial hypertension	1.163